全文获取类型
收费全文 | 3924篇 |
免费 | 185篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 89篇 |
妇产科学 | 53篇 |
基础医学 | 578篇 |
口腔科学 | 36篇 |
临床医学 | 402篇 |
内科学 | 811篇 |
皮肤病学 | 67篇 |
神经病学 | 371篇 |
特种医学 | 161篇 |
外国民族医学 | 4篇 |
外科学 | 652篇 |
综合类 | 21篇 |
一般理论 | 3篇 |
预防医学 | 214篇 |
眼科学 | 24篇 |
药学 | 270篇 |
中国医学 | 2篇 |
肿瘤学 | 286篇 |
出版年
2023年 | 17篇 |
2022年 | 33篇 |
2021年 | 87篇 |
2020年 | 29篇 |
2019年 | 71篇 |
2018年 | 103篇 |
2017年 | 41篇 |
2016年 | 57篇 |
2015年 | 86篇 |
2014年 | 110篇 |
2013年 | 155篇 |
2012年 | 292篇 |
2011年 | 326篇 |
2010年 | 159篇 |
2009年 | 163篇 |
2008年 | 251篇 |
2007年 | 235篇 |
2006年 | 250篇 |
2005年 | 221篇 |
2004年 | 181篇 |
2003年 | 204篇 |
2002年 | 160篇 |
2001年 | 90篇 |
2000年 | 75篇 |
1999年 | 76篇 |
1998年 | 44篇 |
1997年 | 30篇 |
1996年 | 33篇 |
1995年 | 18篇 |
1994年 | 21篇 |
1993年 | 30篇 |
1992年 | 50篇 |
1991年 | 29篇 |
1990年 | 31篇 |
1989年 | 35篇 |
1988年 | 28篇 |
1987年 | 32篇 |
1986年 | 37篇 |
1985年 | 25篇 |
1984年 | 22篇 |
1983年 | 22篇 |
1982年 | 16篇 |
1979年 | 15篇 |
1978年 | 15篇 |
1976年 | 8篇 |
1973年 | 8篇 |
1972年 | 11篇 |
1970年 | 8篇 |
1966年 | 10篇 |
1965年 | 8篇 |
排序方式: 共有4124条查询结果,搜索用时 15 毫秒
981.
Ajzenberg D Collinet F Mercier A Vignoles P Dardé ML 《Journal of clinical microbiology》2010,48(12):4641-4645
We developed an easy-to-use method for genotyping Toxoplasma gondii isolates in a single multiplex PCR assay with 15 microsatellite markers. This method was validated by testing 26 reference isolates that had been characterized with other sets of markers. 相似文献
982.
983.
984.
Benjamin L Cotté FE Philippe C Mercier F Bachelot T Vidal-Trécan G 《European journal of cancer (Oxford, England : 1990)》2012,48(6):912-920
Although efficacy and tolerability are classical criteria for treatment choice, patient adherence and tariff issues related to novel oral anticancer drugs may also influence therapeutic decisions. We estimated the relative influence of efficacy, tolerability, expected adherence and route of administration of a chemotherapy treatment on 203 French physicians' preferences who participated in a Discrete Choice Experiment (DCE), a quantitative method used to elicit preferences. From a questionnaire with six scenarii, respondents had to choose between two treatments which differed with respect to these four attributes. Scenarii were first presented in a curative setting then in a palliative setting. Efficacy, tolerability and expected adherence had two modalities (good versus moderate) and route of administration had three modalities (intravenous (€286-379/session), oral with the current tariff (€28/consultation), oral with a hypothetical tariff (€114)). Efficacy was the reference criterion in choosing a treatment whatever the therapeutic goal (β: 2.114, p<0.0001 in curative setting versus β: 1.063, p<0.0001 in palliative setting). The oral route of administration was important but only in a palliative setting (β: 0.612, p=0.035, and β: 0.506, p<0.0001 for the current and hypothetical tariff, respectively). Removing the efficacy attribute from logistic regression model, tolerability (β: 1.228, p=0.0001) and expected adherence (β: 1.223, p=0.0001) were influent in curative setting while the route of administration was still predominant in palliative setting (β: 0.431, p<0.0001). Results suggest that economic considerations as well as therapeutic efficacy play a significant role in choosing a treatment. Preference for oral chemotherapy with a hypothetical tariff for a patient support programme should be considered for the development of therapeutic education and healthcare coordination, currently not taken into account in the tariff of oral chemotherapy. 相似文献
985.
The success of endocrine therapies for hormone receptor-positive breast cancer and trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 (HER2)-positive tumors has paved the way for the clinical development of several other metastatic breast cancer (MBC)-targeted therapies. Although the benefit of the anti-VEGF (vascular endothelial growth factor) monoclonal antibody bevacizumab in the MBC setting has become a topic of debate, clinical trial results are accumulating, and phase 3 evaluations are ongoing for newer HER2-targeted agents (pertuzumab and trastuzumab-maytansine immunoconjugate) and VEGF-targeted agents (aflibercept), as well as dual, epidermal growth factor receptor/HER2-targeted agents (afatinib [BIBW 2992] and neratinib), multitargeted tyrosine kinase inhibitors (sunitinib and pazopanib), and mammalian target of rapamycin (everolimus) and poly (ADP-ribose) polymerase 1 inhibitors (iniparib, olaparib). These agents as well as other novel classes of anticancer agents are being tested in clinical trials with the potential of addressing unmet therapeutic needs in the MBC patient population. 相似文献
986.
Persson EC Graubard BI Evans AA London WT Weber JP Leblanc A Chen G Lin W McGlynn KA 《International journal of cancer. Journal international du cancer》2012,131(9):2078-2084
Dichlorodiphenyltrichloroethane (p,p'-DDT), an organochlorine pesticide known to have deleterious health effects in humans, has been linked to hepatocellular carcinoma (HCC) in rodents. A recent study has reported that p,p'-DDT and its most persistent metabolite, dichlorodiphenyldichloroethylene (p,p'-DDE), may also be associated with HCC in humans. To examine whether there is an association between p,p'-DDT and/or p,p'-DDE in a population at high-risk of developing HCC, a nested case-control study was conducted within the 83,794 person Haimen City Cohort in China. Sera and questionnaire data were collected from all participants between 1992 and 1993. This study included 473 persons who developed HCC and 492 who did not, frequency matched on sex, age and area of residence. p,p'-DDT and p,p'-DDE levels were determined by mass spectrometry. Hepatitis B viral infection status (based on hepatitis B virus surface antigen; HBsAg) was also determined. p,p'-DDT and/or p,p'-DDE serum levels were significantly associated with sex, area of residence, occupation, alcohol consumption and cigarette smoking. Adjusting for age, sex, area of residence, HBsAg, family history of HCC, history of acute hepatitis, smoking, alcohol, occupation (farmer vs. other) and levels of p,p'-DDT or p,p'-DDE, odds ratios (OR) and 95% confidence intervals (CI) were calculated via unconditional logistic regression. Overall, the highest quintile of p,p'-DDT was associated with an increased risk of HCC, OR = 2.96 95% CI; 1.19-7.40. There were no statistically significant associations with p,p'-DDE. Overall, these results suggest that recent exposure to p,p'-DDT may increase risk of HCC. 相似文献
987.
988.
Chattopadhyay N Cai Z Pignol JP Keller B Lechtman E Bendayan R Reilly RM 《Molecular pharmaceutics》2010,7(6):2194-2206
Our purpose was to develop a human epidermal growth factor receptor-2 (HER-2) targeted nanotechnology-based radiosensitizer. HER-2 is overexpressed in 20-30% of all breast cancers and up to 2-fold higher in locally advanced disease (LABC). Trastuzumab was derivatized with a polyethylene glycol (OPSS-PEG-SVA) cross-linker to produce trastuzumab-PEG-OPSS. These immunoconjugates were analyzed by SDS-PAGE, and their immunoreactivity was assessed by flow cytometry using HER-2 overexpressing SK-BR-3 breast cancer cells. Reacting trastuzumab with increasing ratios of PEG resulted in an increase in molecular weight from approximately 148 kDa to 243 kDa, associated with increasing PEG substitution (0.6 to 18.9 PEG chains per trastuzumab). Attachment of approximately 7 PEG chains per trastuzumab resulted in 56% retention in immunoreactivity assessed by flow cytometry. The conjugates were then linked to 30 nm AuNPs. Using a novel (123)iodine-radiotracer based assay that overcomes the current limitations of spectrophotometric quantification of biological molecules on AuNPs we estimate 14.3 ± 2.7 antibodies were attached to each AuNP when 2 × 10(11) AuNPs were reacted with 20 μg of trastuzumab-PEG-OPSS. Specificity of trastuzumab-PEG-AuNPs for HER-2 and internalization in SK-BR-3 cells was demonstrated by comparing the uptake of trastuzumab-PEG-AuNPs or PEG-AuNPs by darkfield microscopy. The ability of trastuzumab-PEG-AuNPs in combination with 300 kVp X-rays to enhance DNA double strand breaks (DSBs) in SK-BR-3 cells was assessed by immunofluorescence using the γ-H2AX assay. γ-H2AX assay results revealed 5.1-fold higher DNA-DSBs with trastuzumab-PEG-AuNPs and X-radiation as compared to treatment with X-radiation alone. The trastuzumab-PEG-AuNPs are a promising targeted nanotechnology-based radiosensitizer for improving LABC therapy. The design and systematic approaches taken to surface modify and characterize trastuzumab-PEG-AuNPs described in this study would have application to other molecularly targeted AuNPs for cancer treatment. 相似文献
989.
Jacquin JP Jones S Magné N Chapelle C Ellis P Janni W Mavroudis D Martín M Laporte S 《Breast cancer research and treatment》2012,134(3):903-913
The benefit of taxanes in the adjuvant setting for node-negative (N0) early breast cancer (EBC) has not yet been established. We conducted a meta-analysis of randomized adjuvant trials comparing docetaxel-containing versus non-taxane-containing regimens. The purpose of this study was to determine whether the incorporation of docetaxel improves disease-free survival (DFS) and overall survival (OS) in early stage breast cancer. Studies were retrieved by searching major databases and the proceedings of leading breast cancer conferences. We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) for DFS and OS and obtained pooled estimates using an inverse-variance model. Fourteen randomized phase III studies were included (25,067 patients). The pooled HR estimate was 0.84 (95% CI 0.78-0.89; P < 0.001) favoring docetaxel for DFS and 0.86 (0.78-0.94; P < 0.001) for OS. In N0 patients (4,274 patients), the pooled HR estimate for DFS was 0.86 (0.73-1.00; P = 0.05). The HR for OS was equal to 1 (0.75-1.34). The improvement in DFS with docetaxel-containing regimens was observed across all subgroups (age, under or over 50; number of involved nodes; hormone receptor or HER2 status (including triple negative status), or administration schedule (sequential or concomitant). The addition of docetaxel to a non-taxane-containing regimen improves DFS and OS in high risk EBC patients. The benefit in DFS was seen across all subgroups regardless of nodal status, age, hormone receptor or HER2 status (including triple negative status), or administration schedule. 相似文献
990.
François Marcotte MD Nancy Poirier MD Josephine Pressacco MD Éléonore Paquet MD Lise‐Andrée Mercier MD Annie Dore MD Reda Ibrahim MD Paul Khairy MD PhD 《Congenital heart disease》2009,4(4):216-230
Cardiovascular magnetic resonance (CMR) imaging plays an essential role in the evaluation and follow‐up of adult congenital heart disease (ACHD), providing safe, high‐resolution imaging of some of the most complex anatomies encountered. Unlimited by acoustic windows and capable of tissue characterization, CMR is devoid of ionizing radiation and provides superior three‐dimensional spatial resolution to transthoracic echocardiography and superior temporal resolution to computed tomography, making it the gold standard for various cardiac and great vessel imaging indications in ACHD. In this state‐of‐the art review, we provide an overview of CMR examination methods and detail the various approaches and classical findings in the more common forms of ACHD. Although this review touches upon technical aspects of CMR imaging in ACHD, it is primarily geared toward the adult congenital caregiver (i.e., clinical, interventional, or surgical), highlighting relevant practical considerations. To enhance the clinical utility of this review, numerous examples with intraoperative correlates are provided to highlight our imaging approaches for various defects. As CMR image acquisition may be time consuming and requires patient collaboration (e.g., intermittent breath holding), a systemic approach is required to maximize efficiency. A thorough knowledge of ACHD anatomy and natural history is essential in maximizing image interpretation. Proficient scanning is further enabled by clearly outlined study objectives with prior documentation of interventional and surgical procedures, where applicable. 相似文献